SCHEDULE: Lynwood Capital Discloses 6.1% Stake in Rein Therapeutics

Lynwood Capital Management and associated entities have reported a 6.1% beneficial ownership stake in Rein Therapeutics, Inc. following a recent equity offering.

Summary

• Lynwood Capital Management Inc., Benjamin Shapiro, and Lynwood Opportunities Master Fund have filed a Schedule 13G reporting collective beneficial ownership of 4,750,000 shares of Rein Therapeutics, Inc. common stock.
• The reported stake represents 6.1% of the company's total outstanding common stock.
• The ownership calculation is based on 78,039,032 shares outstanding as of May 4, 2026, following the closing of a company offering.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure; while it confirms institutional participation in a recent capital raise, it is a passive filing with no indication of strategic shifts.

Positives

• Institutional investment interest from Lynwood Capital Management indicates external confidence in the company's equity offering.
• The filing confirms the successful completion of a capital raise by the issuer as of May 4, 2026.

Negatives

• The filing represents a passive investment position, which does not imply active management or strategic intervention by the reporting persons.

Risks

• The investment is subject to market volatility inherent in the biotechnology and therapeutics sector.
• The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing control, limiting the potential for immediate shareholder activism.

Future Outlook

The reporting persons have certified that they do not intend to influence or change the control of the issuer, suggesting a passive investment strategy.

Management Comments

• Benjamin Shapiro, as President and CIO of the Investment Manager, confirms the accuracy of the ownership reporting.

Industry Context

StockSavvy.ai notes that the entry of institutional capital following a public offering is a standard indicator of market absorption for biotech equity raises, reflecting investor appetite for the issuer's clinical or commercial pipeline.

Comparison to Industry Standards

• The 6.1% stake is consistent with typical institutional 'block' positions in small-cap biotechnology firms.
• The filing follows standard regulatory requirements for entities crossing the 5% ownership threshold under Section 13(d) of the Exchange Act.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a validation of the company's recent equity offering.
• The increased float from the recent offering may impact short-term share price volatility.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

Rein Therapeutics, Schedule 13G, Lynwood Capital, Institutional Ownership, Equity Offering, Biotech Investment